Table I.
Prostate cancer patient clinicopathological characteristics and clinical features.
| Variable | All Cases (%) | lncRNA-ATB expression
|
χ2 | P-value | |
|---|---|---|---|---|---|
| Low (%) | High (%) | ||||
| Age | |||||
| ≤70 | 39 (68.4) | 22 (56.4) | 17 (43.6) | 0.004 | 0.952 |
| >70 | 18 (31.6) | 10 (55.6) | 8 (44.4) | ||
| Histological grade | |||||
| G1 + G2 | 35 (61.4) | 24 (68.6) | 11 (31.4) | 5.691 | 0.017 |
| G3 | 22 (38.6) | 8 (36.4) | 14 (63.6) | ||
| Preoperative PSA | |||||
| <10 ng/ml | 21 (36.8) | 18 (85.7) | 3 (14.3) | 11.811 | 0.001 |
| ≥10 ng/ml | 36 (63.2) | 14 (38.9) | 22 (61.1) | ||
| Pathological stage | |||||
| I + II | 37 (64.9) | 26 (70.2) | 11 (29.7) | 8.550 | 0.003 |
| III + IV | 20 (35.1) | 6 (30.0) | 14 (70.0) | ||
| Gleason score | |||||
| 4–6 | 22 (38.6) | 16 (72.7) | 6 (27.3) | 4.003 | 0.045 |
| 7–10 | 35 (61.4) | 16 (45.7) | 19 (54.3) | ||
| Lymph node metastasis | |||||
| Negative | 49 (86.0) | 31 (63.3) | 18 (36.7) | 7.198 | 0.007 |
| Positive | 8 (14.0) | 1 (12.5) | 7 (87.5) | ||
| Surgical margin status | |||||
| Negative | 47 (82.5) | 28 (59.6) | 19 (40.4) | 1.283 | 0.257 |
| Positive | 10 (17.5) | 4 (40.0) | 6 (60.0) | ||
| Angiolymphatic invasion | |||||
| Negative | 40 (70.2) | 27 (67.5) | 13 (32.5) | 7.029 | 0.008 |
| Positive | 17 (29.8) | 5 (29.4) | 12 (70.6) | ||
| Biochemical recurrence | |||||
| Negative | 43 (75.4) | 29 (67.4) | 14 (32.6) | 9.081 | 0.003 |
| Positive | 14 (24.6) | 3 (21.4) | 11 (78.6) | ||